CBD for Breast Cancer Primary Tumors

Part of paid clinical trials in Charleston, South Carolina.

Sponsor
Medical University of South Carolina
Study ID
NCT06148038
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CBD Oral — DRUG
    CBD Oral 175mg or 350mg twice daily for 5 days-56 days
  • Control — OTHER
    Placebo Control

Study Details

This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using permuted block randomization with random block sizes of 6 or 12. The time window between CBD or placebo initiation and surgery will be between 5 and 56 days.

Key Dates

Start date
Jun 15, 2026
Status verified
Apr 2026
Primary completion
Mar 25, 2028
Completion
Mar 25, 2029

Study Design

Enrollment
84 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CBD Oral
    CBD Oral 175mg or 350mg twice daily for 5-56 days
  • Placebo Comparator: Placebo control
    Placebo control Oral twice daily for 5-56 days

Primary Outcome Measure

CBD and cell proliferation [ Time Frame: 2 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical University of South CarolinaCharlestonSouth Carolina29425
HCC Clinical Trials Office
[email protected]
843-792-9321

Find similar trials in Charleston, SC

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Medical University of South Carolina· Charleston, SC

Related Studies